DarioHealth’s Dario shows reduction of diabetes patient hospital readmissions

DarioHealth (DRIO) announced new research presented by Sanofi (SNY) at the Academy of Managed Care Pharmacy’s 2023 annual conference Nexus (“AMCP-Nexus”), demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes. The research examined real-world claims data to determine whether users engaged with Dario’s solution demonstrated less costly utilization of hospital-related utilization and found clinically meaningful impacts: 36% reduction in 30-day hospital readmission rate; and 1.6 fewer days in the hospital. The research is part of an ongoing study initiative conducted jointly by Dario and Sanofi U.S., and complements previously published studies presented at ISPOR demonstrating Dario’s ability to reduce all-cause healthcare utilization by 9% and inpatient hospitalizations by 23%. Two additional analyses presented at AMCP Nexus by Sanofi U.S. examined clinical improvements in the same exact and propensity-score matched populations of Dario users and non-Dario users living with Type 2 diabetes.